Peripheral insulin resistance in obese girls with hyperandrogenism is related to oxidative phosphorylation and elevated serum free fatty acids

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 9, 2015, Pages E726-E733

  Cree Green, Melanie ^a,b   Newcomer, Bradley R ^c   Coe, Gregory ^a   Newnes, Lindsey ^a   Baumgartner, Amy ^a   Brown, Mark S ^d   Pyle, Laura ^a   Reusch, Jane E ^d,e   Nadeau, Kristen J ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Department of Pediatrics University of Colorado School of Medicine and Department of Biostatistics and Informatics Colorado School of Public Health ^*  (United States)

Author keywords

Hyperandrogenic syndrome; Hyperandrogenism; Insulin resistance; Mitochondria; Obesity

Indexed keywords

ADENOSINE DIPHOSPHATE; ANDROGEN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PHOSPHATE; PHOSPHORUS 31;

ADOLESCENT; ADULT; ANAEROBIC GLYCOLYSIS; ANDROGEN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE INTENSITY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISOMETRIC EXERCISE; LEUKOCYTE COUNT; MUSCLE FUNCTION; MUSCLE MITOCHONDRION; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OXIDATIVE PHOSPHORYLATION; PH; PHOSPHATE BLOOD LEVEL; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; THROMBOCYTE COUNT; BLOOD; CHILDHOOD OBESITY; COMPLICATION; CROSS-SECTIONAL STUDY; HYPERINSULINISM; LIPID METABOLISM; METABOLISM; OVARY POLYCYSTIC DISEASE; PHYSIOLOGY; SKELETAL MUSCLE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LIPID METABOLISM; MUSCLE, SKELETAL; OXIDATIVE PHOSPHORYLATION; PEDIATRIC OBESITY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84929662646     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00619.2014     Document Type: Article

References (59)

1. Angioni S, Sanna S, Magnini R, Melis GB, Fulghesu AM. The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome. Gynecol Endocrinol 27: 468–474, 2011.
2. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86: 66–71, 2001.
3. Bamman MM, Caruso JF. Resistance exercise countermeasures for space flight: implications of training specificity. J Strength Condition Res 14: 45–49, 2000.
4. Bjorntorp P. The android woman—a risky condition. J Intern Med 239: 105–110, 1996.
5. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 20: 291–302, 1996.
6. Cara JF. Insulin-like growth factors, insulin-like growth factor binding proteins and ovarian androgen production. Horm Res 42: 49–54, 1994.
7. Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab 94: 157–163, 2009.
8. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 192: 585–594, 2007.
9. Cree-Green M, Newcomer BR, Brown M, Hull A, West AD, Singel D, Reusch JE, McFann K, Regensteiner JG, Nadeau KJ. Method for controlled mitochondrial perturbation during phosphorus MRS in children. Med Sci Sports Exerc 46: 2030–2036, 2014.
10. Cree-Green M, Newcomer BR, Brown MS, Baumgartner AD, Bergman B, Drew B, Regensteiner JG, Pyle L, Reusch JE, Nadeau KJ. Delayed skeletal muscle mitochondrial ADP recovery in youth with type 1 diabetes relates to muscle insulin resistance. Diabetes 64: 383–392, 2014.
11. Cree MG, Fram RY, Herndon DN, Qian T, Angel C, Green JM, Mlcak R, Aarsland A, Wolfe RR. Human mitochondrial oxidative capacity is acutely impaired after burn trauma. Am J Surg 196: 234–239, 2008.
12. Cree MG, Newcomer BR, Herndon DN, Qian T, Sun D, Morio B, Zwetsloot JJ, Dohm GL, Fram RY, Mlcak RP, Aarsland A, Wolfe RR. PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond) 4: 9, 2007.
13. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 83: 4420–4425, 1998.
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774–800, 1997.
15. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65: 499–507, 1987.
16. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174, 1989.
17. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96: 801–810, 1995.
18. Eriksen MB, Glintborg D, Nielsen MF, Jakobsen MA, Brusgaard K, Tan Q, Gaster M. Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance. Biochem Biophys Res Commun 451: 622–626, 2014.
19. Eriksen MB, Minet AD, Glintborg D, Gaster M. Intact primary mitochondrial function in myotubes established from women with PCOS. J Clin Endocrinol Metab 96: E1298–E1302, 2011.
20. Fleischman A, Kron M, Systrom DM, Hrovat M, Grinspoon SK. Mitochondrial function and insulin resistance in overweight and normalweight children. J Clin Endocrinol Metab 94: 4923–4930, 2009.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972.
22. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol 25: 335–343, 2009.
23. Fulghesu A, Magnini R, Portoghese E, Angioni S, Minerba L, Melis GB. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome. J Adolesc Health 46: 474–481, 2010.
24. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, Hermann AP. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 155: 337–345, 2006.
25. Guo ZK. Intramyocellular lipid kinetics and insulin resistance. Lipids Health Dis 6: 18, 2007.
26. Hutchison SK, Teede HJ, Rachon D, Harrison CL, Strauss BJ, Stepto NK. Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome. Diabetologia 55: 1424–1434, 2012.
27. Item F, Heinzer-Schweizer S, Wyss M, Fontana P, Lehmann R, Henning A, Weber M, Boesiger P, Boutellier U, Toigo M. Mitochondrial capacity is affected by glycemic status in young untrained women with type 1 diabetes but is not impaired relative to healthy untrained women. Am J Physiol Regul Integr Comp Physiol 301: R60–R66, 2011.
28. Karakelides H, Irving BA, Short KR, O’Brien P, Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes 59: 89–97, 2010.
29. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51: 2944–2950, 2002.
30. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Res Med 14: 26–30, 1990.
31. Larson-Meyer DE, Newcomer BR, Hunter GR, Hetherington HP, Weinsier RL. 31P MRS measurement of mitochondrial function in skeletal muscle: reliability, force-level sensitivity and relation to whole body maximal oxygen uptake. NMR Biomed 13: 14–27, 2000.
32. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98: 4565–4592, 2013.
33. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 307: 384–387, 2005.
34. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 92: 430–436, 2007.
35. McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Yoo R, Chang RJ, Foster CM, Marshall JC. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab 91: 1714–1722, 2006.
36. Minet AD, Gaster M. ATP synthesis is impaired in isolated mitochondria from myotubes established from type 2 diabetic subjects. Biochem Biophys Res Commun 402: 70–74, 2010.
37. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16: 347–363, 2010.
38. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16: 347–363, 2010.
39. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115: 3587–3593, 2005.
40. Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JEB. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 95: 513–521, 2010.
41. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 154: 384–389, 1986.
42. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72: 83–89, 1991.
43. Newcomer BR, Boska MD. Adenosine triphosphate production rates, metabolic economy calculations, pH, phosphomonoesters, phosphodiesters, and force output during short-duration maximal isometric plantar flexion exercises and repeated maximal isometric plantar flexion exercises. Muscle Nerve 20: 336–346, 1997.
44. Nur MM, Newman IM, Siqueira LM. Glucose metabolism in overweight Hispanic adolescents with and without polycystic ovary syndrome. Pediatrics 124: e496–e502, 2009.
45. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 1017–1023, 2002.
46. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140–1142, 2003.
47. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79: 265–271, 1994.
48. Rabol R, Svendsen PF, Skovbro M, Boushel R, Schjerling P, Nilas L, Madsbad S, Dela F. Skeletal muscle mitochondrial function in polycystic ovarian syndrome. Eur J Endocrinol 165: 631–637, 2011.
49. Rico-Sanz J, Thomas EL, Jenkinson G, Mierisova S, Iles R, Bell JD. Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by 1H-MRS. J Appl Physiol 87: 2068–2072, 1999.
50. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 88: 131–138, 2007.
51. Scalzo RL, Peltonen GL, Binns SE, Shankaran M, Giordano GR, Hartley DA, Klochak AL, Lonac MC, Paris HL, Szallar SE, Wood LM, Peelor FF, 3rd Holmes WE, Hellerstein MK, Bell C, Hamilton KL, Miller BF. Greater muscle protein synthesis and mitochondrial biogenesis in males compared with females during sprint interval training. FASEB J 28: 2705–2714, 2014.
52. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371: 1131–1141, 2014.
53. Sirikul B, Hunter GR, Larson-Meyer DE, Desmond R, Newcomer BR. Relationship between metabolic function and skeletal muscle fatigue during a 90 s maximal isometric contraction. Physiol Appliq Nutr Metab 32: 394–399, 2007.
54. Skov V, Glintborg D, Knudsen S, Jensen T, Kruse TA, Tan Q, Brusgaard K, Beck-Nielsen H, Hojlund K. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes 56: 2349–2355, 2007.
55. Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, Beck-Nielsen H, Hojlund K. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS One 3: e2466, 2008.
56. Thompson JR, Swanson SA, Casale GP, Johanning JM, Papoutsi E, Koutakis P, Miserlis D, Zhu Z, Pipinos II. Gastrocnemius mitochondrial respiration: are there any differences between men and women? J Surg Res 185: 206–211, 2013.
57. van den Boogaart A. 96 MRUI MANUAL V.3. A User’s Guide to the Magnetic Resonance User Interface Software Package. Delft: Delft Technical Univ. Press, 1997.
58. Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD, Siscovick DS, Bibbins-Domingo K. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 117: 6–13, 2011.
59. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 92: 10619–10623, 1995.